Document is current
Any future updates will be listed below
-
Authors
Boccalini, Cecilia
Peretti, Debora Elisa
Scheffler, Max
Mu, Linjing
Griffa, Alessandra
Testart, Nathalie
Allali, Gilles
Prior, John O.
Ashton, Nicholas J.
Zetterberg, Henrik
Blennow, Kaj
Frisoni, Giovanni B.
Garibotto, Valentina
-
Funding
Funding for this research was provided by:
University of Geneva
- License Information
-
More Information
Article History
Received: 30 October 2024
Accepted: 25 January 2025
First Online: 18 February 2025
Declarations
:
: The local Ethics Committee approved the imaging studies, which have been conducted under the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice. Each subject or their relatives provided voluntary written informed consent to participate in the studies.
: VG received research support and speaker fees through her institution from Healthcare, Siemens Healthineers, Novo Nordisk. Janssen and Novartis. GBF has received support, payment, consulting fees, or honoraria through his institution for lectures, presentations, speaker bureaus, manuscript writing, or educations events from: Biogen, Roche, Diadem, Novo Nordisk, GE Healthcare, OM Pharma, and Eisai. GA has served at scientific advisory boards and consultants for Roche and Lilly and received honoraria for lectures from Lilly and Schwabe Pharma. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials, and participated in educational programs for Biogen, Eisai, and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this article. The other authors have no conflicts of interest to disclose.
